跳到正文
營養與代謝隨機對照試驗3 分鐘閱讀

2型糖尿病:空腹血糖日間波動大,與嚴重低血糖和死亡相關

MoveVitals 編輯部 · 研究發表 · 解讀更新

原文:Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). · Diabetologia · 2017 · 論文原文 ↗

先看重點

在胰島素試驗DEVOTE的二次分析中,空腹自測血糖的日間變異越大,校正前嚴重低血糖(HR 4.11,95%置信區間3.15至5.35)和全因死亡(HR 1.58,95%置信區間1.23至2.03)風險越高。這兩項關聯在校正後仍成立,但與主要心血管不良事件的關聯不再成立,且該設計只能說明相關性。

證據類型

隨機對照試驗

解讀依據

公開摘要

閱讀重點

對照與不確定性

研究在問什麼

血糖逐日起伏不定,除平均水平之外可能還有獨立風險。作者利用DEVOTE試驗(在心血管高風險的2型糖尿病患者中比較德谷胰島素與甘精胰島素U100)來檢驗:空腹血糖的日間變異是否與嚴重低血糖和心血管結局有關。

研究對象與方法

對DEVOTE試驗做二次分析,該試驗為雙盲、隨機、事件驅動、以達標為目標的試驗。變異定義為早餐前自測血糖(SMBG)的標準差:每月只取與研究中心聯絡前記錄的3次讀數,取對數後求方差,對各月方差取平均再開平方。用Cox比例風險模型在合併後的試驗族群中分析其與嚴重低血糖、主要心血管不良事件(MACE)及全因死亡的關聯,並做了校正基線特徵和最近一次HbA1c的敏感性分析。摘要沒有給出參與者人數。

主要發現

以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。

  1. 1
    校正前,變異越大,嚴重低血糖(HR 4.11,95%置信區間3.15至5.35)、MACE(HR 1.36,95%置信區間1.12至1.65)和全因死亡(HR 1.58,95%置信區間1.23至2.03)的風險越高。
  2. 2
    患者的變異指標增加一倍,對應嚴重低血糖風險為2.7倍,MACE為1.2倍,全因死亡為1.4倍。
  3. 3
    與嚴重低血糖和全因死亡的關聯在校正後仍然存在;摘要沒有給出校正後的具體數值。
  4. 4
    與MACE的關聯在校正基線特徵及基線HbA1c(HR 1.19,95%置信區間0.96至1.47)或最近一次HbA1c(HR 1.21,95%置信區間0.98至1.49)後不再成立。

限制與不確定性

  1. 1
    這是隨機試驗內的二次觀察性分析,不能說明降低變異就能降低風險。
  2. 2
    變異僅來自每月3次空腹自測讀數,可能存在較大噪聲。
  3. 3
    參與者為使用基礎胰島素、心血管高風險的2型糖尿病患者,結果未必適用於風險較低或使用其他治療的人。
  4. 4
    極端血糖或健康狀況較差可能同時造成讀數不穩和事件發生,校正未必能完全排除這一點。

日常健康啟示

在這個高風險試驗族群中,空腹血糖逐日大幅波動與更多嚴重低血糖和死亡同時出現。因此平穩的讀數值得與醫療團隊討論,但研究並未說明如何做到。不要自行調整胰島素劑量。

如何連結自己的資料

如果你測空腹血糖或佩戴連續血糖監測儀,可以看清晨讀數在不同天之間的離散程度,使用同一臺血糖儀或感測器,並保持測量時間一致。把規律反映給醫師,而不是對單次讀數做出反應。

如何理解這類證據

隨機分組有助於因果推斷,仍須檢查分配、盲法、失去追蹤、追蹤時間和具體對照;標為隨機試驗不自動意味著高確定性。

作者的結構化摘要 English

以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。

Aims/hypothesis

The Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of insulin degludec with that of insulin glargine U100 (100 units/ml) in patients with type 2 diabetes at high risk of cardiovascular events. This paper reports a secondary analysis investigating associations of day-to-day fasting glycaemic variability (pre-breakfast self-measured blood glucose [SMBG]) with severe hypoglycaemia and cardiovascular outcomes.

Methods

In DEVOTE, patients with type 2 diabetes were randomised to receive insulin degludec or insulin glargine U100 once daily. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In this article, day-to-day fasting glycaemic variability was based on the standard deviation of the pre-breakfast SMBG measurements. The variability measure was calculated as follows. Each month, only the three pre-breakfast SMBG measurements recorded before contact with the site were used to determine a day-to-day fasting glycaemic variability measure for each patient. For each patient, the variance of the three log-transformed pre-breakfast SMBG measurements each month was determined. The standard deviation was determined as the square root of the mean of these monthly variances and was defined as day-to-day fasting glycaemic variability. The associations between day-to-day fasting glycaemic variability and severe hypoglycaemia, MACE and all-cause mortality were analysed for the pooled trial population with Cox proportional hazards models. Several sensitivity analyses were conducted, including adjustments for baseline characteristics and most recent HbA_(1c).

Results

Day-to-day fasting glycaemic variability was significantly associated with severe hypoglycaemia (HR 4.11, 95% CI 3.15, 5.35), MACE (HR 1.36, 95% CI 1.12, 1.65) and all-cause mortality (HR 1.58, 95% CI 1.23, 2.03) before adjustments. The increased risks of severe hypoglycaemia, MACE and all-cause mortality translate into 2.7-, 1.2- and 1.4-fold risk, respectively, when a patient's day-to-day fasting glycaemic variability measure is doubled. The significant relationships of day-to-day fasting glycaemic variability with severe hypoglycaemia and all-cause mortality were maintained after adjustments. However, the significant association with MACE was not maintained following adjustment for baseline characteristics with either baseline HbA_(1c) (HR 1.19, 95% CI 0.96, 1.47) or the most recent HbA_(1c) measurement throughout the trial (HR 1.21, 95% CI 0.98, 1.49).

Conclusions/interpretation

Higher day-to-day fasting glycaemic variability is associated with increased risks of severe hypoglycaemia and all-cause mortality.

Trial registration

ClinicalTrials.gov NCT01959529.

來源與署名

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB, DEVOTE Study Group.

Diabetologia · 2017-09-15

DOI: 10.1007/s00125-017-4423-z ↗PubMed · 28913575 ↗Europe PMC · 所記錄的開放授權: cc by ↗

摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。

MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱

來源查核日期 2026-11-01

實用健康指南

放在一起讀

·隨機試驗統合分析

更早的進食視窗與更大的體重和胰島素獲益相關,優於晚間進食

彙總41項隨機對照試驗(2287名參與者,介入時間中位數8週)發現,限時進食比日常飲食體重低2.15 kg(95%置信區間−2.56至−1.74),而早吃比晚吃體重多降1.15 kg(95%置信區間−1.86至−0.45)。多數試驗較短,只有6個研究組檢驗了早間進食,結局是身體和血液指標,不是心臟病發作或死亡。

BMJ Medicine

重點論文精講閱讀論文 →
·隨機對照試驗

限熱量飲食再加上午8點至下午4點進食視窗,1年減重無明顯額外優勢

139名肥胖患者都按限制熱量的飲食進食,其中一組再加上上午8:00至下午4:00的進食視窗,12個月平均體重變化為−8.0 kg,單純限熱量組為−6.3 kg。淨差值−1.8 kg(95%置信區間−4.0至0.4;P=0.11)無統計學意義,該區間既不能排除視窗確有獲益,也不能排除毫無作用。

The New England Journal of Medicine

重點論文精講閱讀論文 →
·隨機對照試驗

20人住院試驗:超加工飲食讓人每天多攝取508 kcal並增重

20名成年人在醫院研究病房住了28天,兩種選單各吃2週、想吃多少吃多少:超加工選單讓他們每天多攝取508 kcal(±106,標準誤,P=0.0001),體重增加0.9 kg;未加工選單則讓體重減輕0.9 kg。樣本小、週期短、食物全程由研究方提供,既不能說明日常生活中的長期結果,也無法確定是食物的哪種特點導致多吃。

Cell Metabolism

重點論文精講閱讀論文 →
·隨機對照試驗

地中海飲食加橄欖油或堅果與心血管事件減少相關(更正後的試驗)

在7447名55至80歲、心血管風險較高的西班牙成年人中,被分到加特級初榨橄欖油(風險比0.69,95%置信區間0.53至0.91)或加堅果(風險比0.72,0.54至0.95)的地中海飲食組,發生主要心血管事件的風險低於被告知減少脂肪的對照組。試驗存在隨機化失誤,2013年的報告已撤回並重新估算,證據有力但並不完美。

The New England Journal of Medicine

重點論文精講閱讀論文 →
營養與代謝 →